<DOC>
	<DOCNO>NCT02836613</DOCNO>
	<brief_summary>The main purpose study evaluate much galcanezumab get body give injection skin two different device . This study measure much galcanezumab reach blood stream test affect calcitonin-gene related peptide ( CGRP ) blood . Information side effect may occur collect . The study last 20 week participant . Screening require within 45 day prior start study .</brief_summary>
	<brief_title>A Study Galcanezumab Healthy Participants .</brief_title>
	<detailed_description />
	<criteria>Overtly healthy determine medical history physical examination Have body mass index ( BMI ) 19.0 35.0 kilogram per meter square ( kg/mÂ² ) Have clinical laboratory test result within normal reference range investigative site , result acceptable deviation judge clinically significant investigator Have previously complete withdrawn study study investigate galcanezumab , previously receive galcanezumab Have allergy either humanized monoclonal antibody , diphenhydramine , epinephrine , methylprednisolone Intend use overthecounter prescription medication within 7 day prior dose study ( especially systemic glucocorticoid , immunomodulatory drug , drug propensity dermal reaction , drug know hepatic toxicity , etc ) . Stable dos hormone replacement therapy ( HRT ) allow inclusion discretion investigator Have lymphoma , leukemia , malignancy within past 5 year except basal cell squamous epithelial carcinoma skin resect evidence metastatic disease 3 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>